CAPONE, EMILY
 Distribuzione geografica
Continente #
EU - Europa 555
NA - Nord America 144
AS - Asia 75
AF - Africa 1
Totale 775
Nazione #
FR - Francia 234
US - Stati Uniti d'America 144
SE - Svezia 131
IT - Italia 108
IE - Irlanda 32
VN - Vietnam 29
IN - India 11
NL - Olanda 11
CZ - Repubblica Ceca 9
CN - Cina 8
HK - Hong Kong 8
KR - Corea 7
PH - Filippine 6
UA - Ucraina 6
BE - Belgio 5
DE - Germania 5
RU - Federazione Russa 5
GB - Regno Unito 3
JP - Giappone 3
MY - Malesia 3
PL - Polonia 2
RO - Romania 2
BY - Bielorussia 1
PT - Portogallo 1
ZA - Sudafrica 1
Totale 775
Città #
Stockholm 130
Chieti 55
Paris 55
Dublin 32
Ashburn 31
Dong Ket 27
Boardman 25
Redmond 10
Mumbai 7
Rome 7
San Jose 7
Central 6
Beijing 5
Treviso 5
Brussels 4
Dallas 4
Parma 4
Pescara 4
Poway 4
Angeles City 3
Barrington 3
Frankfurt am Main 3
Kuala Lumpur 3
London 3
Milan 3
Nerviano 3
Ugong Norte 3
Bengaluru 2
Brooklyn 2
Council Bluffs 2
Gorzkow 2
Hanoi 2
Kobe 2
L’Aquila 2
Mulazzano 2
Noci 2
Pioltello 2
Amsterdam 1
Ann Arbor 1
Arezzo 1
Auburn 1
Austin 1
Basking Ridge 1
Berlin 1
Brest 1
Brignais 1
Buyeo 1
Cape Town 1
Chicago 1
Fleming Island 1
Fort Lee 1
Galati 1
Gatchina 1
Herselt 1
Houston 1
Iasi 1
Kochi 1
Lake Forest 1
Lanciano 1
Los Angeles 1
Maarssen 1
Malmo 1
Memphis 1
New York 1
Padova 1
Piedimonte 1
Portici 1
Portimão 1
Pune 1
San Diego 1
San Salvo 1
Shrewsbury 1
Suwon 1
Suzhou 1
Turin 1
Utrecht 1
Verona 1
Voorhees Township 1
Watertown 1
Yeonsu-gu 1
Totale 509
Nome #
LGALS3BP antibody-drug-conjugate and its use for the treatment of cancer, file e4233f18-e93d-2860-e053-6605fe0a460a 205
EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors, file e4233f18-9584-2860-e053-6605fe0a460a 84
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates, file e4233f17-0528-2860-e053-6605fe0a460a 39
Repurposing a psychoactive drug for children with cancer: p27 Kip1-dependent inhibition of metastatic neuroblastomas by Prozac, file e4233f17-65ca-2860-e053-6605fe0a460a 37
HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies, file e4233f17-9070-2860-e053-6605fe0a460a 36
BAG3 induces fibroblasts to release key cytokines involved in pancreatic cell migration, file e4233f18-9550-2860-e053-6605fe0a460a 34
miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance, file e4233f15-4484-2860-e053-6605fe0a460a 27
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma, file e4233f16-e783-2860-e053-6605fe0a460a 26
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma, file e4233f17-7c4c-2860-e053-6605fe0a460a 26
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma, file e4233f17-8230-2860-e053-6605fe0a460a 26
Dual PDK1/aurora kinase a inhibitors reduce pancreatic cancer cell proliferation and colony formation, file e4233f17-828e-2860-e053-6605fe0a460a 26
Antibody-drug conjugates: The new frontier of chemotherapy, file e4233f17-d812-2860-e053-6605fe0a460a 25
Therapeutic potential of antibody‐drug conjugate‐based therapy in head and neck cancer: A systematic review, file e4233f18-b812-2860-e053-6605fe0a460a 25
Normal breathing releases SARS-CoV-2 into the air, file e4233f18-76d4-2860-e053-6605fe0a460a 21
HER-3: Hub for escape mechanisms, file e4233f17-868b-2860-e053-6605fe0a460a 20
HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications, file ad221ea8-7481-49fb-87f1-0833300bc915 18
MYC regulates metabolism through vesicular transfer of glycolytic kinases, file e4233f18-8cae-2860-e053-6605fe0a460a 18
Targeting vesicular lgals3bp by an antibody-drug conjugate as novel therapeutic strategy for neuroblastoma, file e4233f18-51bf-2860-e053-6605fe0a460a 17
Visualizing Galectin-3 Binding Protein Expression with ImmunoPET, file 3b7de6c7-ad99-4c24-a0bc-07418603358a 15
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer, file e4233f17-e4be-2860-e053-6605fe0a460a 14
Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma, file b5a2d813-9694-474b-b6b6-8c6087c42654 12
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans, file e4233f18-f07d-2860-e053-6605fe0a460a 6
Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma, file 964f00b4-a892-436e-b396-946d6d41f49f 5
LGALS3BP is a potential target of antibody-drug conjugates in oral squamous cell carcinoma, file a289b249-cb14-4c5e-b641-511a38584754 4
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target, file b81e5c5f-a118-4da4-a6b3-237f50c2d07c 4
EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo., file 5a50a26e-3c0b-49e6-872f-11fd81f9a2f3 3
Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target, file 7c19329b-fd7d-4917-a573-5a2064ea8924 3
ABCC3 is a novel target for the treatment of pancreatic cancer, file e4233f17-eac9-2860-e053-6605fe0a460a 2
Totale 778
Categoria #
all - tutte 2.425
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.425


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206 0 0 0 0 0 0 1 0 1 1 3 0
2020/202144 1 0 1 0 1 1 1 3 0 4 4 28
2021/202260 3 3 9 2 5 6 5 0 8 3 11 5
2022/2023257 5 3 5 10 6 32 47 12 23 33 71 10
2023/2024407 16 16 23 45 36 235 24 12 0 0 0 0
Totale 778